Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Promoting More Conservative Prescribing

Promoting More Conservative Prescribing CLINICIAN’S CORNER COMMENTARY more skeptical approach to using drugs, prescribers will lack Gordon D. Schiff, MD the will and the skills to resist ubiquitous promotional mes- William L. Galanter, MD, PhD sages encouraging them to reach for newer and often more expensive medications. LTHOUGH MEDICAL AND PHARMACY CURRICULA Such skepticism needs to be grounded in historical and and journals are rich with information about current lessons that offer reasons for precaution. Lessons drugs and treatment of specific diseases, there is from iatrogenic events related to agents such as thalido- Aa paucity of education on ways to become effec- mide, phen-fen, or rofecoxib (Vioxx); recognition that new tive lifetime prescribers. Two recent reports from the medications are tested in limited numbers of patients with Association of American Medical Colleges (AAMC) few comorbidities, typically for a relatively short time; and lamented the current state of pharmacology teaching and disquieting revelations that promotional activities distort the disturbing extent of pharmaceutical industry influ- what prescribers learn about drugs are lessons worth learn- ence at all stages of medical education. Given the well- ing and incorporating into prescribing decision making. Al- documented prevalence of medication-related harm and though the attitudes and behaviors recommended in http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Promoting More Conservative Prescribing

JAMA , Volume 301 (8) – Feb 25, 2009

Loading next page...
 
/lp/american-medical-association/promoting-more-conservative-prescribing-8DEGsm3w6y
Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2009.195
pmid
19244196
Publisher site
See Article on Publisher Site

Abstract

CLINICIAN’S CORNER COMMENTARY more skeptical approach to using drugs, prescribers will lack Gordon D. Schiff, MD the will and the skills to resist ubiquitous promotional mes- William L. Galanter, MD, PhD sages encouraging them to reach for newer and often more expensive medications. LTHOUGH MEDICAL AND PHARMACY CURRICULA Such skepticism needs to be grounded in historical and and journals are rich with information about current lessons that offer reasons for precaution. Lessons drugs and treatment of specific diseases, there is from iatrogenic events related to agents such as thalido- Aa paucity of education on ways to become effec- mide, phen-fen, or rofecoxib (Vioxx); recognition that new tive lifetime prescribers. Two recent reports from the medications are tested in limited numbers of patients with Association of American Medical Colleges (AAMC) few comorbidities, typically for a relatively short time; and lamented the current state of pharmacology teaching and disquieting revelations that promotional activities distort the disturbing extent of pharmaceutical industry influ- what prescribers learn about drugs are lessons worth learn- ence at all stages of medical education. Given the well- ing and incorporating into prescribing decision making. Al- documented prevalence of medication-related harm and though the attitudes and behaviors recommended in

Journal

JAMAAmerican Medical Association

Published: Feb 25, 2009

References